ISLAMABAD — In a major push to boost domestic manufacturing and bring advanced biotech to the country, Islamabad is set to host the high-profile Pakistan–China Pharmaceutical & Healthcare B2B Investment Conference 2026 from July 17–18, 2026.
The two-day summit is organized through a joint collaboration between the Special Investment Facilitation Council (SIFC), the Ministry of National Health Services, Regulations & Coordination, and the Drug Regulatory Authority of Pakistan (DRAP).
The conference serves as a strategic matchmaking platform, bringing together top Pakistani pharmaceutical, healthcare, and biotechnology companies with leading Chinese industrial investors, manufacturers, and technology partners.
Expanding Bilateral Medical Ties
The upcoming conference will focus heavily on shifting Pakistan from a finished-medicine importer to a high-value producer. Primary objectives of the event include:
- B2B Partnerships & Joint Ventures: Setting up direct commercial deals to manufacture active pharmaceutical ingredients (APIs) locally within Pakistan.
- Biotech & Tech Transfer: Introducing modern Chinese manufacturing technologies to upgrade local laboratory standards and production speeds.
- Unlocking New Capital: Creating streamlined investment pipelines backed by SIFC policy relaxations to make the domestic healthcare sector highly attractive to foreign venture capital.
By bringing regulatory authorities and corporate leaders under one roof, the government aims to fast-track approval processes, reduce medicine production costs, and pave the way for a self-reliant, export-oriented healthcare industry.
